Semaglutide Injection Side Effects: Clinical Guide & Biomarkers

Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide injections are GLP-1 receptor agonists that can cause gastrointestinal side effects in 20-50% of users, with nausea, vomiting, and diarrhea being most common during early titration phases. These effects often diminish within 4-8 weeks as the body acclimates to the medication.

Side effect tolerance varies significantly among individuals based on genetics, existing metabolic conditions, and dose escalation speed. PlexusDx emphasizes precision-wellness framing: understanding your unique risk profile through biomarkers and genetic context can support more personalized conversations with your healthcare provider about whether compounded semaglutide is appropriate for you.

Common Gastrointestinal Side Effects and Their Timeline

The most frequently reported side effects include nausea (occurs in approximately 25-40% of patients), vomiting (5-10%), diarrhea (20-30%), and constipation (10-20%). These effects typically emerge within the first 1-2 weeks of starting therapy or after dose increases.

Most gastrointestinal symptoms peak around week 2-4 and resolve by week 8-12 as the body adapts. Slower dose titration schedules and taking injections with consistent meals can reduce symptom severity. Some patients experience mild, manageable nausea without progressing to vomiting.

Dose Titration Schedules and Side Effect Severity Across Protocols

Dose titration speed directly influences side effect risk. Standard protocols begin at 0.25 mg weekly and increase by 0.25 mg every 4 weeks, while microdose protocols start at 0.1-0.15 mg weekly with slower escalation. Slower titration reduces acute nausea but extends the treatment initiation period.

Individual tolerance varies widely based on age, BMI, gastric sensitivity, and concurrent medications. Working with a provider to select a titration schedule that balances efficacy goals with tolerability is essential for treatment adherence and long-term success.

Titration Protocol	Starting Dose	Weekly Increase	Typical Nausea Rate	Timeline to Goal
Standard escalation	0.25 mg/week	+0.25 mg every 4 weeks	25-35%	12-16 weeks
Microdose approach	0.1-0.15 mg/week	+0.05-0.1 mg every 1-2 weeks	10-15%	20-24 weeks
Rapid escalation	0.5 mg/week	+0.5 mg weekly	40-50%	4-8 weeks
Individual tailoring	Provider-determined	Provider-adjusted	5-20%	Varies by tolerance

Non-Gastrointestinal Side Effects and Metabolic Considerations

Beyond digestive symptoms, patients may experience fatigue, headache, dizziness, or appetite suppression that extends beyond the intended therapeutic effect. Hypoglycemia risk increases in patients also taking insulin or other diabetes medications, requiring provider-coordinated monitoring.

Some patients report changes in taste perception, mild dehydration, or transient elevation in calcitonin levels (though clinical significance remains debated). Regular hydration, adequate protein intake, and close provider monitoring help mitigate these effects. Any concerning symptoms warrant immediate communication with your healthcare provider.

Who May Face Higher Risk: Clinical Factors and Provider Decision-Making

Patients with a history of pancreatitis, severe gastroparesis, or thyroid cancer should not use semaglutide due to absolute contraindications. Those with pre-existing nausea disorders, sensitive gag reflexes, or rapid gastric emptying patterns may experience more pronounced side effects and benefit from slower titration or alternative agents.

Providers evaluate individual risk through medical history, current medication profile, and metabolic status. If side effects become intolerable despite dose reduction or slower titration, alternative formulations (such as oral semaglutide or compounded tirzepatide) or different medication classes may be considered in consultation with your healthcare team.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context around individual variations in GLP-1 receptor sensitivity and metabolic processing. Genetic variants in GLP1R (rs6923761) and GIPR (rs1800437) pathways can inform whether your body may be more or less responsive to GLP-1 signaling, which may correlate with side effect tolerance, though individual responses remain highly variable.

The genetic test examines predispositions in peptide pathways rather than predicting exact medication response or side effect occurrence. Results like FTO (rs9939609) and MC4R (rs17782313) variants reveal metabolic context that should be interpreted with your qualified healthcare provider to support more informed conversations about treatment selection and dose strategy.

Understanding your genetic predispositions can support a collaborative discussion with your provider about whether compounded semaglutide aligns with your individual risk-benefit profile, what titration schedule may work best for you, and whether alternative compounded GLP-1 options might offer better tolerability.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.